After Needham and Stifel Nicolaus gave MKS Instruments (NASDAQ: MKSI) a Buy rating last month, the company received another Buy, this time from Benchmark Co. Analyst Mark Miller maintained a Buy rating on MKS Instruments today and set a price target of $184.00. The company’s shares closed last Wednesday at $112.00, close to its 52-week low of $110.26.
According to TipRanks.com, Miller is a 5-star analyst with an average return of 18.9% and a 56.1% success rate. Miller covers the Technology sector, focusing on stocks such as Axcelis Technologies, Advanced Energy, and Onto Innovation.
Currently, the analyst consensus on MKS Instruments is a Strong Buy with an average price target of $183.44, which is a 65.6% upside from current levels. In a report issued on April 13, Deutsche Bank also maintained a Buy rating on the stock with a $170.00 price target.
See today’s best-performing stocks on TipRanks >>
MKS Instruments’ market cap is currently $6.22B and has a P/E ratio of 10.90.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MKS Instruments, Inc. engages in the provision of instruments, subsystems, and process control solutions to measure, control, power, monitor, and analyze parameters of manufacturing processes. It operates through the Vacuum and Analysis; and Light and Motion segments. The Vacuum and Analysis segment comprises pressure measurement and control, flow measurement and control, gas and vapor delivery, gas composition analysis, residual gas analysis, leak detection, control technology, ozone generation and delivery, RF & DC power, reactive gas generation, and vacuum technology components. The Light and Motion segment includes lasers, photonics, sub-micron positioning, vibration control, and optics instruments. The company was founded in 1961 and is headquartered in Andover, MA.
Read More on MKSI:
- EQT (EQT) Gets a Buy Rating from Siebert Williams Shank & Co
- Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN) and Sanofi (OtherSNYNF)
- Paypal Holdings (PYPL) Receives a Hold from Needham
- Wedbush Sticks to Its Buy Rating for LendingClub (LC)
- Merit Medical Systems (MMSI) Receives a Buy from Needham
